ストックスクリーナーアプリを入手
0.7529
10.72%
0.0729
アフターアワーズ：
.79
0.0371
+4.93%
Fate Therapeutics Inc (FATE) 最新ニュース
Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average – Here’s What Happened - Defense World
FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Equities Analysts Issue Forecasts for FATE FY2025 Earnings - Defense World
Weekly Research Analysts’ Ratings Updates for Fate Therapeutics (FATE) - Defense World
Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties - MSN
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Fate Therapeutics at Leerink Conference: Strategic Shift to FT-819 By Investing.com - Investing.com UK
Fate Therapeutics at Barclays Conference: Strategic Shift to Autoimmune Focus - Investing.com UK
Fate Therapeutics (NASDAQ:FATE) Rating Lowered to “Sell” at StockNews.com - Defense World
Fate Therapeutics price target lowered to $2.50 from $3 at BofA - TipRanks
Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush - Defense World
Fate Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target - Yahoo Finance
Stifel Nicolaus Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $3.00 - Defense World
Wedbush Reaffirms Neutral Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Needham & Company LLC Reiterates Hold Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Wells Fargo & Company Has Lowered Expectations for Fate Therapeutics (NASDAQ:FATE) Stock Price - Defense World
Is Fate Therapeutics Inc (NASDAQ: FATE) A Good Investment For New Investors Now? - Stocks Register
Optimistic Outlook for Fate Therapeutics’ FT819 in Cell-Therapy Space Amid Promising Phase 1 Results - TipRanks
Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties - TipRanks
Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating By Investing.com - Investing.com Canada
Stifel cuts Fate Therapeutics stock target to $3, maintains hold By Investing.com - Investing.com Canada
Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties - TipRanks
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus - Nasdaq
Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating - Investing.com India
Y Intercept Hong Kong Ltd Invests $58,000 in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics: Q4 Earnings Snapshot - mySA
Fate Therapeutics Advances CAR T-cell Programs Amid Financial Losses - TipRanks
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates - MSN
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - Marketscreener.com
Fate Therapeutics shares rise as Q4 revenue tops estimates By Investing.com - Investing.com South Africa
Fate Therapeutics shares rise as Q4 revenue tops estimates - Investing.com
Fate Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com UK
Fate Therapeutics, Inc Q4 Loss Misses Estimates - Nasdaq
Fate Therapeutics: Q4 Earnings Snapshot -March 05, 2025 at 04:13 pm EST - Marketscreener.com
FATE THERAPEUTICS INC SEC 10-K Report - TradingView
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics (NASDAQ:FATE) Upgraded by StockNews.com to Hold Rating - Defense World
FATE stock touches 52-week low at $1.03 amid sharp annual decline - Investing.com
Fate Therapeutics (FATE) Expected to Announce Earnings on Monday - MarketBeat
Fate Therapeutics (FATE) Projected to Post Earnings on Monday - Defense World
iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World
Fate Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.75 Average PT from Analysts - Armenian Reporter
10.70%
大文字化:
|
ボリューム (24 時間):